Latest News

Seroba Co-leads a €1.2 million New Investment in Biosensia.

Dublin, Ireland, 9 November 2011.  Biosensia, a point of care diagnostics company, has secured €1.2 million in new funding as part of the company’s plans to advance its regulatory and commercial strategy for its platform in Europe and the US. The funding round was co-led by Seroba Bioventures and ACT Venture Capital and also included existing investors, Atlantic Bridge. ...


Seroba Kernel Co-leads £5m Investment in Veryan Medical.

Dublin, Ireland, November 1, 2011. Seroba Kernel Life Sciences (Seroba Kernel) and Imperial Innovations Group (Innovations) have co-led a £5m funding round into Veryan Medical, which is developing innovative solutions for vascular disease using its unique Biomimics 3D™ stent technology. Seroba Kernel and Innovations each invested approximately half of the funds raised.  Dr...


Sir Gregory Winter joins Covagen’s Scientific Advisory Board.

Switzerland, September 20, 2011. Covagen announced today that Sir Gregory Winter is joining its Scientific Advisory Board.  Sir Gregory Winter is a member of the Medical Research Council’s Laboratory of Molecular Biology (LMB) in Cambridge, and a Fellow of Trinity College Cambridge (UK).  He has served LMB as a Head of Division, Deputy Director and Acting Director.  His...


< back to home page